This content was published on 06 April 2022 – 11:14
Cairo, Apr 6 (EFE) .- The World Health Organization (WHO) stated this Thursday that it hopes that India will soon resolve the problems detected in the production of its Covaxin anticovid vaccine to resume the distribution of the serum through the mechanism Covax, which was suspended last week.
The head of Infectious Risk Prevention of the WHO Eastern Mediterranean office, Abdinasir Abubakar, said in a virtual press conference that he hopes that “the Indian authorities can overcome the problems in a short period of time to start again with the production” of its anticovid serum.
The expert said from Cairo that they are working with the Indian authorities to identify problems in the production of the vaccine in their factories since “the world needs more vaccines since there are not enough” in the world.
Likewise, he explained that “the problems identified will not have an impact on the capacity of the vaccine, only in the process where the problems have been identified.”
On April 2, the WHO suspended the supply of Bharat Biotech’s anticovid vaccine, Covaxin, under the Covax mechanism, attributing it to manufacturing deficiencies.
The African continent relies almost entirely on the Covax mechanism, an initiative led by the Global Alliance for Vaccines and Immunization (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO.
According to WHO data, last January the barrier of one billion doses of vaccine sent through Covax to countries with fewer resources was overcome. EFE
ijm/amr/ah
© EFE 2022. The redistribution and rebroadcasting of all or part of the contents of Efe’s services is expressly prohibited, without the prior and express consent of Agencia EFE SA
–
